{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:48:30Z","timestamp":1758440910089,"version":"3.44.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"DOI":"10.7759\/cureus.92754","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:43:00Z","timestamp":1758343380000},"source":"Crossref","is-referenced-by-count":0,"title":["Administration of Onasemnogene Abeparvovec in an Infant With Spinal Muscular Atrophy and PCR-Confirmed SARS-CoV-2 Infection"],"prefix":"10.7759","author":[{"given":"Ikushi","family":"Shimomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manaka","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell JR","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al.. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017, 377:1713-22. 10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular\u00a0atrophy","volume":"74","author":"Chand D","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, et al.. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular\u00a0atrophy. J Hepatol. 2021, 74:560-6. 10.1016\/j.jhep.2020.11.001","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27363","article-title":"Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy","volume":"64","author":"Kichula EA","year":"2021","unstructured":"Kichula EA, Proud CM, Farrar MA, Kwon JM, Saito K, Desguerre I, McMillan HJ. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021, 64:413-27. 10.1002\/mus.27363","journal-title":"Muscle Nerve"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: safety and early outcomes","volume":"146","author":"Waldrop MA","year":"2020","unstructured":"Waldrop MA, Karingada C, Storey MA, et al.. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020, 146:10.1542\/peds.2020-0729","journal-title":"Pediatrics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bdcasr.2024.100022","article-title":"Acute liver failure worsened after respiratory syncytial virus infection in an infant with spinal muscular atrophy type I after receiving onasemnogene abeparvovec","volume":"2","author":"Sakemi S","year":"2024","unstructured":"Sakemi S, Fujita T, Kaku N, et al.. Acute liver failure worsened after respiratory syncytial virus infection in an infant with spinal muscular atrophy type I after receiving onasemnogene abeparvovec. Brain Dev Case Rep. 2024, 2:100022. 10.1016\/j.bdcasr.2024.100022","journal-title":"Brain Dev Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman AG","year":"2020","unstructured":"Feldman AG, Parsons JA, Dutmer CM, Veerapandiyan A, Hafberg E, Maloney N, Mack CL. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020, 225:252-258.e1. 10.1016\/j.jpeds.2020.05.044","journal-title":"J Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03715-2","article-title":"Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study","volume":"20","author":"Chen T","year":"2025","unstructured":"Chen T, Chen Q, Ye J, Wu Y, Liu T, Zhang Y. Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study. Orphanet J Rare Dis. 2025, 20:215. 10.1186\/s13023-025-03715-2","journal-title":"Orphanet J Rare Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss KA","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al.. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022, 28:1390-7. 10.1038\/s41591-022-01867-3","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2013020","article-title":"Natural history of asymptomatic SARS-CoV-2 infection","volume":"383","author":"Sakurai A","year":"2020","unstructured":"Sakurai A, Sasaki T, Kato S, et al.. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med. 2020, 383:885-6. 10.1056\/NEJMc2013020","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/382776-administration-of-onasemnogene-abeparvovec-in-an-infant-with-spinal-muscular-atrophy-and-pcr-confirmed-sars-cov-2-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:43:04Z","timestamp":1758343384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/382776-administration-of-onasemnogene-abeparvovec-in-an-infant-with-spinal-muscular-atrophy-and-pcr-confirmed-sars-cov-2-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.92754","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}